Assembly Biosciences Inc
$ 22.96
1.91%
12 Jun - close price
- Market Cap 455,004,000 USD
- Current Price $ 22.96
- High / Low $ 23.68 / 22.35
- Stock P/E 287.00
- Book Value 12.50
- EPS 0.08
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.05 %
- ROE -0.06 %
- 52 Week High 39.71
- 52 Week Low 16.50
About
Assembly Biosciences, Inc. is a clinical-stage biotechnology company in the United States. The company is headquartered in South San Francisco, California.
Analyst Target Price
$50.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-19 | 2025-11-10 | 2025-08-06 | 2025-05-08 | 2025-03-20 | 2024-11-07 | 2024-08-08 | 2024-05-08 | 2024-03-27 | 2023-11-08 | 2023-08-09 |
| Reported EPS | -0.54 | 2.48 | -0.72 | -1.33 | -1.17 | -1.57 | -1.51 | -2.05 | -1.66 | -2.15 | -0.27 | -0.32 |
| Estimated EPS | -0.6367 | -0.8467 | -1.57 | -1.61 | -1.6 | -1.75 | -2.02 | -2.23 | -3.23 | -2.88 | -0.23 | -0.29 |
| Surprise | 0.0967 | 3.3267 | 0.85 | 0.28 | 0.43 | 0.18 | 0.51 | 0.18 | 1.57 | 0.73 | -0.04 | -0.03 |
| Surprise Percentage | 15.1877% | 392.9019% | 54.1401% | 17.3913% | 26.875% | 10.2857% | 25.2475% | 8.0717% | 48.6068% | 25.3472% | -17.3913% | -10.3448% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.7 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ASMB
2026-06-09 13:09:41
Assembly Biosciences highlighted its antiviral and liver disease development strategy, discussing upcoming decisions for its HSV-2 program with Gilead, the expansion of its hepatitis delta candidate into cholestatic liver diseases, and expected clinical data readouts. The company is focused on recurrent genital herpes caused by HSV-2 and hepatitis delta, now broadening into primary biliary cholangitis and primary sclerosing cholangitis. Key milestones include a decision on the HSV-2 cost and profit share with Gilead, initiation of a Phase 2 hepatitis delta study, and data readouts for liver disease programs in 2027 and 2028.
2026-06-08 21:39:23
This article mentions Assembly Biosciences' interest in Gilead's HSV plan and the expansion of its ABI-6250 liver pipeline. No further details are provided in the given content.
2026-06-08 14:48:00
This article from Stock Traders Daily analyzes Assembly Biosciences (ASMB) using AI models, identifying weak near- and mid-term sentiment but a strong long-term outlook. It provides specific algorithmic trading strategies—Long Position, Momentum Breakout, and Risk Hedging Short—along with multi-timeframe signal analysis for support and resistance levels. The report highlights elevated downside risk due to a lack of additional long-term support signals.
2026-06-06 12:10:46
Assembly Biosciences (ASMB) CEO and President Jason A. Okazaki received a grant of 50,750 Restricted Stock Units (RSUs) at no cash cost. This grant, approved on March 29, 2026, became issuable after stockholders approved an amendment to the company's 2018 Stock Incentive Plan on June 4, 2026. The RSUs will vest in four approximately equal annual installments from March 29, 2027, to March 29, 2030, contingent on continued service, and after this award, Okazaki directly holds 163,354 shares of common stock.
2026-06-06 11:39:23
Assembly Biosciences is awaiting a clinical development plan from Gilead Sciences for its herpes simplex virus (HSV) programs, ABI-5366 and ABI-1179, after Gilead opted into both. Concurrently, Assembly is expanding its ABI-6250 program, an NTCP inhibitor, into hepatitis delta and cholestatic liver diseases like primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC). The company is also seeking a partner for its hepatitis B program, ABI-4334, and has a cash runway extending beyond 2028 due to recent financing.
2026-06-06 10:40:20
Assembly Biosciences (NASDAQ: ASMB) has granted 8,000 stock options to its director, John G. McHutchison. These options have an exercise price of $24.11 per share and are set to expire on June 4, 2036. The vesting of these options is contingent on continuous service and will occur on the earlier of June 4, 2027, or the company’s 2027 annual meeting of stockholders.
